Published in Trials on March 07, 2015
Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol (2010) 3.47
Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate. Gastroenterology (2006) 2.68
Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2009) 2.33
The prevalence and characterization of simple hepatic cysts by ultrasound examination. Br J Radiol (1989) 2.01
Polycystic disease of the liver. Hepatology (2004) 1.94
The prevalence of simple renal and hepatic cysts detected by spiral computed tomography. Clin Radiol (2003) 1.86
Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data. Gastroenterology (2013) 1.66
Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol (2007) 1.54
Diagnosis and management of polycystic liver disease. Nat Rev Gastroenterol Hepatol (2013) 1.46
Hepatic cysts: treatment with alcohol. AJR Am J Roentgenol (1985) 1.39
Medical and surgical treatment options for polycystic liver disease. Hepatology (2010) 1.39
Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. Clin J Am Soc Nephrol (2010) 1.36
Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. J Am Soc Nephrol (2013) 1.33
Results of percutaneous sclerotherapy and surgical treatment in patients with symptomatic simple liver cysts and polycystic liver disease. World J Gastroenterol (2007) 1.24
Evaluation of a gastrointestinal symptoms questionnaire. Dig Dis Sci (2006) 1.11
Symptomatic hepatic cysts: percutaneous drainage and sclerosis. Radiology (1994) 1.07
Single-session alcohol sclerotherapy in symptomatic benign hepatic cysts performed with a time of exposure to alcohol of 10 min: initial results. Eur Radiol (2003) 1.04
Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases. Hepatology (2013) 1.03
Treatment of symptomatic hepatic cyst by percutaneous instillation of Pantopaque. AJR Am J Roentgenol (1976) 1.02
Regulation and deregulation of cholangiocyte proliferation. J Hepatol (2000) 1.02
Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study. Diabetes Res Clin Pract (2013) 0.95
Hepatic cysts treated with percutaneous ethanol sclerotherapy: time to extend the indications to haemorrhagic cysts and polycystic liver disease. Eur Radiol (2014) 0.92
Successful treatment of a hepatic cyst by one-shot instillation of minocycline chloride. Gastroenterology (1992) 0.89
The occurrence of asymptomatic and symptomatic simple hepatic cysts. A prospective, hospital-based study. Clin Radiol (2005) 0.88
Safety, tolerability, and pharmacokinetics of a single dose of pasireotide long-acting release in healthy volunteers: a single-center Phase I study. Eur J Endocrinol (2012) 0.88
Evaluating health-related quality of life in patients with polycystic liver disease and determining the impact of symptoms and liver volume. Liver Int (2014) 0.87
Percutaneous aspiration and ethanolamine oleate sclerotherapy for sustained resolution of symptomatic polycystic liver disease: an initial experience. AJR Am J Roentgenol (2009) 0.83
Percutaneous treatment of symptomatic non-parasitic benign liver cysts with 20% NaCl solution. Med Arh (2011) 0.82
Effects of Subcutaneous Pasireotide on Cardiac Repolarization in Healthy Volunteers: a Single‐Center, Phase I, Randomized, Four‐Way Crossover Study. J Clin Pharmacol (2014) 0.77